scholarly journals Corrigendum to: Formation and immunomodulatory function of meningeal B cell aggregates in progressive CNS autoimmunity

Brain ◽  
2021 ◽  
Author(s):  
Meike Mitsdoerffer ◽  
Giovanni Di Liberto ◽  
Sarah Dötsch ◽  
Christopher Sie ◽  
Ingrid Wagner ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Aggregates ◽  
Cns Autoimmunity ◽  
Immunomodulatory Function

scholarly journals Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2

2016 ◽  
Vol 113 (17) ◽  
pp. 4777-4782 ◽  
Author(s):  
Ulf Schulze-Topphoff ◽  
Michel Varrin-Doyer ◽  
Kara Pekarek ◽  
Collin M. Spencer ◽  
Aparna Shetty ◽  
...  
Keyword(s):  
B Cell ◽  
Immune Modulation ◽  
Brain Mri ◽  
Dimethyl Fumarate ◽  
Autoimmune Encephalomyelitis ◽  
Cns Inflammation ◽  
Alternative Pathways ◽  
Mhc Ii ◽  
Fumaric Acid Ester ◽  
Cns Autoimmunity

Dimethyl fumarate (DMF) (BG-12, Tecfidera) is a fumaric acid ester (FAE) that was advanced as a multiple sclerosis (MS) therapy largely for potential neuroprotection as it was recognized that FAEs are capable of activating the antioxidative transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway. However, DMF treatment in randomized controlled MS trials was associated with marked reductions in relapse rate and development of active brain MRI lesions, measures considered to reflect CNS inflammation. Here, we investigated the antiinflammatory contribution of Nrf2 in DMF treatment of the MS model, experimental autoimmune encephalomyelitis (EAE). C57BL/6 wild-type (WT) and Nrf2-deficient (Nrf2−/−) mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide 35–55 (p35–55) for EAE induction and treated with oral DMF or vehicle daily. DMF protected WT and Nrf2−/− mice equally well from development of clinical and histologic EAE. The beneficial effect of DMF treatment in Nrf2−/− and WT mice was accompanied by reduced frequencies of IFN-γ and IL-17–producing CD4+ cells and induction of antiinflammatory M2 (type II) monocytes. DMF also modulated B-cell MHC II expression and reduced the incidence of clinical disease in a B-cell–dependent model of spontaneous CNS autoimmunity. Our observations that oral DMF treatment promoted immune modulation and provided equal clinical benefit in acute EAE in Nrf2−/− and WT mice, suggest that the antiinflammatory activity of DMF in treatment of MS patients may occur through alternative pathways, independent of Nrf2.

scholarly journals Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression

2016 ◽  
Vol 3 (5) ◽  
pp. e272 ◽  
Author(s):  
Michel Varrin-Doyer ◽  
Kara L. Pekarek ◽  
Collin M. Spencer ◽  
Claude C.A. Bernard ◽  
Raymond A. Sobel ◽  
...  
Keyword(s):  
B Cell ◽  
Disease Progression ◽  
Cell Aggregates

Memory B-cell aggregates in skin biopsy are diagnostic for primary Sjögren’s syndrome

2010 ◽  
Vol 35 (3) ◽  
pp. 241-247 ◽  
Author(s):  
Anne-Marie Roguedas ◽  
Jacques-Olivier Pers ◽  
Gilles Lemasson ◽  
Valérie Devauchelle ◽  
Gabriel J. Tobón ◽  
...  
Keyword(s):  
Skin Biopsy ◽  
B Cell ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Cell Aggregates ◽  
Primary Sjogren’S Syndrome ◽  
Memory B Cell ◽  
Primary Sjögren's Syndrome ◽  
Sjögren‘S Syndrome

scholarly journals Differentiating Benign From Malignant Bone Marrow B-Cell Lymphoid Aggregates: A Statistical Analysis of Distinguishing Features

2015 ◽  
Vol 139 (2) ◽  
pp. 233-240 ◽  
Author(s):  
Abbey Johnston ◽  
Russell K. Brynes ◽  
Kaveh Naemi ◽  
Niloufar Reisian ◽  
Deepty Bhansali ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Distribution Patterns ◽  
Cell Aggregates ◽  
Diagnostic Challenge ◽  
Specific Distribution ◽  
History Of ◽  
Characteristic Features ◽  
Distinguishing Features ◽  
Lymphoid Aggregates

Context Lymphoid aggregates are seen in a minority of bone marrow biopsy specimens, and when present, their neoplastic nature is often apparent by morphologic evaluation. However, the distinction between benign and malignant aggregates can be a diagnostic challenge when there are multiple aggregates with no documented history of lymphoma. Objective To aid in the distinction between benign and malignant B-cell lymphoid aggregates. Design Previously, we described specific distribution patterns for B and T lymphocytes within bone marrow aggregates. To statistically analyze the significance of these patterns as well as previously reported criteria, we examined 128 bone marrow specimens with benign aggregates and 78 specimens with documented malignant B-cell aggregates and calculated specific odds ratios (ORs) and 95% confidence intervals (CIs) to aid in differentiating between benign and malignant B-cell aggregates. Results Aggregates with infiltrative edges (OR, 80.54; 95% CI, 31.76–204.21), a B-cell pattern (OR, 30.08; 95% CI, 13.28–68.10), paratrabecular location (OR, 10.17; 95% CI, 3.96–26.12), size greater than 600 μm (OR, 6.83: 95% CI, 3.61–12.93), or cytologic atypia correlated with malignancy. Conclusion When taken collectively, the presence of more than 2 of these characteristic features was strongly predictive of malignancy.

scholarly journals The immunomodulatory function of human amniotic fluid stromal cells on B lymphocytes

2018 ◽  
Vol 1 (1) ◽  
pp. 122-133
Author(s):  
Qun Xue ◽  
Zhou Yin ◽  
Nagam Varshithreddy ◽  
Han-si Liang ◽  
Ming-yuan Wang ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Amniotic Fluid ◽  
B Cell ◽  
B Lymphocytes ◽  
Stromal Cells ◽  
Cell Activity ◽  
Costimulatory Molecules ◽  
Cell Subpopulation ◽  
Human Amniotic Fluid ◽  
Immunomodulatory Function

Current treatments for B cell-mediated disease are mainly based on global B cell depletion, thereby eliminating pathogenic B cells as well as Breg subsets. A more refined modulation of B cell activity could prove beneficial for patient treatment.Objective:To investigate the immunomodulatory function of human amniotic fluid stromal cells (hAFSCs) on different subpopulation of B lymphocytes.Methods:hAFSCs were isolated and cultured and identified by characteristic phenotypic markers. After coculture of B lymphocytes with hAFSCs, the activation, proliferation, differentiation, as well as apoptosis, cell cycle, and expression of the inhibitory costimulatory molecules B7H1, B7H3, and B7H4 of B lymphocytes were examined in vitro.Results:Coculture with hAFSCs significantly decreased the expression of CD80/CD86, Ki-67 and CFSE expression, on activated B lymphocytes. These might be due to the inhibition of B lymphocyte apoptosis and cell cycle arrest. In activated B lymphocytes, coculture with hAFSCs resulted in a reduced proportion of memory B and plasma cells, reduced amounts of immunoglobulins. hAFSCs could balance the B1 to B2 cell subpopulation ratio. hAFSCs could inhibit the expression of the negative co-inhibitory molecule B7H4 and PD-L1 on the activated B lymphocytes.Conclusion:hAFSCs could inhibit B cell activation, proliferation, and subpopulation differentiation. These might be due to their affect on B cell apoptosis, cell cycle and the expression of costimulatory molecules of human B lymphocytes. Our experiment provided the evidence for hAFSCs as ideal seed cells with therapeutic potential for treating humoral immunity disorders, which were mainly mediated by B lymphocytes.

Sign in / Sign up

Export Citation Format

Share Document